Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689678 | 0.86 | MEN1 (0.52) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4705214 | 0.80 | MAPT (0.41) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4705511 | 0.75 | GAA (0.49) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4706529 | 0.71 | NR1I2 (0.39) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6202984 | 0.71 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL14310487 | 0.70 | AURKA (0.55) | MAPTALDH1A1MEN1KMT2AKCNH3 | |
| SCHEMBL4692835 | 0.69 | MAPT (0.45) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4705192 | 0.69 | NR1I2 (0.40) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL11528609 | 0.69 | ALDH1A1 (0.56) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6205531 | 0.68 | MAPT (0.50) | MAPTSMN1; SMN2ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7112676-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1560832-A1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | DERMATAKIS APOSTOLOS (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004041822-A1 | PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FYN | MAPT 3823/4885SMN1; SMN2 1764/4885ALDH1A1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.